Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stryker update

This article was originally published in The Gray Sheet

Executive Summary

Firm expects to spend at least $50 million a year "over the next few years" to resolve issues related to three previous FDA warning letters, VP Strategy and Investor Relations Katherine Owen said during a Sept. 3 presentation at the Thomas Weisel Partners Healthcare Conference in Boston. In April, the company's biotech division received a letter citing quality system and compliance violations at its Hopkinton, Mass., facility (1"The Gray Sheet" May 5, 2008, In Brief). In 2007, the firm received warning letters stemming from inspections of its Mahwah, N.J., and Carrigtohill, Ireland, plants

Related Content

Ortho Earnings: Stryker Plans Big Compliance Investment In 2009
Stryker warning letter is third in a year



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts